San Diego, CA -- (SBWIRE) -- 05/04/2015 -- An investor, who purchased shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI), filed a lawsuit in the U.S. District Court for the District of New Jersey over alleged violations of Federal Securities Laws by Aerie Pharmaceuticals Inc in connection with certain allegedly false and misleading statements made between August 6, 2014 and April 23, 2015.

Investors who purchased shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) have certain options and for certain investors are short and strict deadlines running. Deadline: June 29, 2015. NASDAQ:AERI investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

According to the complaint the plaintiff alleges on behalf of purchasers of Aerie Pharmaceuticals Inc (NASDAQ:AERI) common shares between August 6, 2014 and April 23, 2015, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between August 6, 2014 and April 23, 2015, defendants made allegedly false and misleading statements and/or allegedly failed to disclose adverse information regarding Aerie Pharmaceuticals Inc's prospects for Rhopressa, including that Rhopressa was not performing as well as timolol and would not lead to commercial success for Aerie Pharmaceuticals Inc , and that as a result of these allegedly false and misleading statements and/or omissions, Aerie Pharmaceuticals Inc securities traded at allegedly artificially inflated prices between August 6, 2014 and April 23, 2015, with its stock price reaching a high of $35.39 per share.

Then on April 23, 2015, after the market closed, Aerie Pharmaceuticals Inc reported the results of its first Phase 3 registration trial (Rocket 1) for Rhopressa, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Aerie Pharmaceuticals Inc said that the trial did not meet its primary efficacy endpoint of demonstrating non-inferiority of IOP lowering for once-daily Rhopressa compared to twice-daily timolol, the most widely used comparator in registration trials for glaucoma.

Shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) declined from over $35.00 per share on April 23, 2015, to as low as $9.64 per share on April 28, 2015.

Those who purchased shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com